Director, Global Publications Lead
$212k/y-$260k/y
Madrigal Pharmaceuticals2 days ago
Highlight
HybridFull-timeDirector
Summary
Madrigal Pharmaceuticals is seeking a Director, Global Publications Lead to join their team in Conshohocken, PA. The role involves leading the development and execution of scientific publications within Madrigal Medical Affairs.
About the Role
As the Director, Global Publications Lead, you will be responsible for defining, prioritizing, and executing global scientific publication needs for internal and external stakeholders. You will manage the annual publications plan, ensuring alignment with medical affairs strategies and clinical development priorities. Your role includes leading the writing and editing of scientific content, overseeing compliance with industry standards, and collaborating with various stakeholders to deliver impactful publications.
About You
Required:
- Advanced degree in a scientific or healthcare discipline (MS, MPH, MD, PharmD, PhD, DNP, etc.). CMPP certification highly desirable.
- Minimum of 10 years of experience in healthcare / clinical practice.
- At least 3 years of experience in Scientific Publications.
- Strong expertise in medical writing, publications planning, and scientific communications.
- Exceptional written and verbal communication skills with meticulous attention to detail.
Preferred:
- Clinical experience in a healthcare environment (e.g., medicine, pharmacy, laboratory, nursing).
- In-depth knowledge of liver disease; experience in cardiometabolic health, or Metabolic dysfunction–associated steatohepatitis (MASH).
- Adaptable and proactive in a fast-paced, evolving environment.
Benefits
- Base salary range of $212k–$260k per year.
- Equity options for all employees.
- Comprehensive benefits including flexible paid time off, medical, dental, vision, and life/disability insurance.
- 401(k) offerings with employer match.
- Mental health benefits through the Employee Assistance Program.
Madrigal Pharmaceuticals
Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), a serious form of fatty liver disease. Left untreated, MASH can lead to progressive liver scarring, cirrhosis, liver failure, liver cancer, need for transplant and premature mortality. Our goal is to halt or reverse liver scarring (fibrosis) and resolve MASH before patients experience the devastating complications of cirrhosis. Learn more about us at www.madrigalpharma.com
Conshohocken, PA